Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-12-19 Merger & Acquisition
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
北京市中伦律师事务所关于《江苏浩欧博生物医药股份有限公司要约收购报告书》的法律意见书
Merger & Acquisition Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding a tender offer report for a company named 江苏浩欧博生物医药股份有限公司. It discusses the details of a partial tender offer acquisition, including the acquirers, shareholding structure, offer price, and legal compliance. The document references the tender offer report and related agreements, and it is clearly a legal opinion on the tender offer transaction. This type of document is related to merger and acquisition activity, specifically a tender offer. It is not a full annual report, earnings release, or other financial report. It is not a simple announcement or certification but a detailed legal opinion on the tender offer report. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (15,000 characters) and content confirm it is the legal opinion itself, not just an announcement or summary.
2024-12-19 Chinese
江苏浩欧博生物医药股份有限公司要约收购报告书
M&A Activity Classification · 100% confidence The document is titled as a "要约收购报告书" which translates to "Tender Offer Report" or "Offer to Purchase Report". It details a partial tender offer by the acquirer (双润正安信息咨询（北京）有限公司) to purchase shares of 江苏浩欧博生物医药股份有限公司. The document includes extensive information about the offer price, number of shares, legal and financial advisors, the purpose of the offer, the timeline, and regulatory compliance references. It is a comprehensive filing related to a takeover bid or merger activity rather than a general financial report, earnings release, or management announcement. The presence of detailed terms of the offer, shareholding changes, and regulatory references aligns with the category of M&A Activity filings. Therefore, the document should be classified under the M&A Activity (TAR) category.
2024-12-19 Chinese
江苏浩欧博生物医药股份有限公司关于双润正安信息咨询（北京）有限公司要约收购公司股份的申报公告
M&A Activity Classification · 95% confidence The document is an announcement regarding a tender offer (要约收购) by a company named 双润正安信息咨询（北京）有限公司 to acquire shares of 江苏浩欧博生物医药股份有限公司. It details the offer price, number of shares to be acquired, offer period, procedures for shareholders to accept or withdraw the offer, and other related information. The document is not a full financial report, earnings release, or management discussion. It is a formal announcement of a capital acquisition activity involving a tender offer. This fits the category of M&A Activity (TAR) filings, which cover merger proposals or takeover bids. The document length is 3547 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is TAR with high confidence.
2024-12-19 Chinese
中国国际金融股份有限公司关于双润正安信息咨询（北京）有限公司要约收购江苏浩欧博生物医药股份有限公司之财务顾问报告
M&A Activity Classification · 95% confidence The document is a detailed financial advisor report related to a partial tender offer (要约收购) by 双润正安信息咨询（北京）有限公司 for shares of 江苏浩欧博生物医药股份有限公司. It includes extensive information about the offer, the parties involved, shareholding structures, legal and regulatory references, and financial advisor opinions. The document is not a simple announcement but a comprehensive report prepared by the financial advisor (中国国际金融股份有限公司) in accordance with relevant securities laws and regulations. It is focused on the tender offer transaction, providing an objective and professional evaluation of the offer, the acquirers, and the implications for the target company. This type of document fits the category of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids, including tender offers. The document is not an Annual Report, Earnings Release, or Regulatory Filing, nor is it a Proxy Solicitation or Voting Results announcement. It is a formal financial advisor report on a tender offer transaction.
2024-12-19 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2024年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedural compliance of the 2024 second extraordinary general meeting (EGM) of shareholders of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the convening, attendance, agenda, and voting procedures of the meeting, confirming their compliance with relevant laws and company articles. This is not a report of financial results, audit, or management discussion, nor is it a voting result announcement. It is a legal opinion related to a shareholders' meeting, which typically falls under regulatory filings or legal proceedings. However, since it is a legal opinion letter specifically about the shareholders' meeting procedures and not a general regulatory announcement or lawsuit update, the best fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous filings that do not fit other categories.
2024-12-16 Chinese
江苏浩欧博生物医药股份有限公司2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary shareholders meeting of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, voting results, and legal witness statements. It does not contain financial statements or detailed financial analysis, but rather the official voting results and procedural compliance of the shareholders meeting. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1424 characters), and it is not an announcement of a report publication but the actual voting results announcement. Therefore, the correct classification is DVA with high confidence.
2024-12-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.